文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N

Department of Neuro-psychiatry, Keio University School of Medicine, Tokyo, Japan.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):707-15. doi: 10.1016/0278-5846(94)90078-7.

Zonisamide, an anticonvulsant developed in Japan, is structurally similar to serotonin. Zonisamide has been proven to have a pharmacological profile that is very similar to that of carbamazepine. Thus, the effect of zonisamide was examined in 24 psychiatric patients: 15 with bipolar manic state, 6 with schizoaffective manic state, and 3 schizophrenic excitement. 2. Approximately 25% of all the patients and 33% of the bipolar manic patients showed remarkable global improvement with the addition of zonisamide. Approximately 71% of all the patients and 80% of the bipolar group had more than moderate global improvement. 3. No serious adverse reactions were found and no patients required zonisamide withdrawal. One patient developed both leukocytosis and mildly abnormal liver function test. One developed leukocytosis and another reported mild sleepiness. These reactions disappeared when zonisamide was discontinued.

唑尼沙胺是一种在日本研发的抗惊厥药物，其结构与血清素相似。已证实唑尼沙胺具有与卡马西平非常相似的药理学特征。因此，对24名精神病患者进行了唑尼沙胺疗效研究：15名双相躁狂状态患者、6名分裂情感性躁狂状态患者和3名精神分裂症兴奋患者。2. 所有患者中约25%以及双相躁狂患者中约33%在加用唑尼沙胺后显示出显著的整体改善。所有患者中约71%以及双相组中80%有中度以上的整体改善。3. 未发现严重不良反应，也没有患者需要停用唑尼沙胺。1名患者出现白细胞增多和肝功能检查轻度异常。1名患者出现白细胞增多，另1名患者报告有轻度嗜睡。停用唑尼沙胺后这些反应消失。

Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N

Department of Neuro-psychiatry, Keio University School of Medicine, Tokyo, Japan.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):707-15. doi: 10.1016/0278-5846(94)90078-7.

Zonisamide, an anticonvulsant developed in Japan, is structurally similar to serotonin. Zonisamide has been proven to have a pharmacological profile that is very similar to that of carbamazepine. Thus, the effect of zonisamide was examined in 24 psychiatric patients: 15 with bipolar manic state, 6 with schizoaffective manic state, and 3 schizophrenic excitement. 2. Approximately 25% of all the patients and 33% of the bipolar manic patients showed remarkable global improvement with the addition of zonisamide. Approximately 71% of all the patients and 80% of the bipolar group had more than moderate global improvement. 3. No serious adverse reactions were found and no patients required zonisamide withdrawal. One patient developed both leukocytosis and mildly abnormal liver function test. One developed leukocytosis and another reported mild sleepiness. These reactions disappeared when zonisamide was discontinued.

唑尼沙胺是一种在日本研发的抗惊厥药物，其结构与血清素相似。已证实唑尼沙胺具有与卡马西平非常相似的药理学特征。因此，对24名精神病患者进行了唑尼沙胺疗效研究：15名双相躁狂状态患者、6名分裂情感性躁狂状态患者和3名精神分裂症兴奋患者。2. 所有患者中约25%以及双相躁狂患者中约33%在加用唑尼沙胺后显示出显著的整体改善。所有患者中约71%以及双相组中80%有中度以上的整体改善。3. 未发现严重不良反应，也没有患者需要停用唑尼沙胺。1名患者出现白细胞增多和肝功能检查轻度异常。1名患者出现白细胞增多，另1名患者报告有轻度嗜睡。停用唑尼沙胺后这些反应消失。